Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.

BACKGROUND: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA(®), AbbVie, Maidenhead, UK), etanercept (Enbrel(®), Pfizer, New York, NY, USA) and ustekinumab (STELARA(®), Janssen Biotech, Inc., Titusville, NJ, USA) are the three biological treatments...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Health Technol Assess
Autors principals: Duarte, Ana, Mebrahtu, Teumzghi, Goncalves, Pedro Saramago, Harden, Melissa, Murphy, Ruth, Palmer, Stephen, Woolacott, Nerys, Rodgers, Mark, Rothery, Claire
Format: Artigo
Idioma:Inglês
Publicat: NIHR Journals Library 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5694897/
https://ncbi.nlm.nih.gov/pubmed/29105621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta21640
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars